Elanco Animal Health (NYSE:ELAN) Hits New 1-Year High – Here’s What Happened
by Scott Moore · The Cerbat GemElanco Animal Health Incorporated (NYSE:ELAN – Get Free Report)’s stock price hit a new 52-week high during trading on Tuesday . The stock traded as high as $23.74 and last traded at $23.4350, with a volume of 763721 shares traded. The stock had previously closed at $23.05.
Wall Street Analysts Forecast Growth
Several brokerages have issued reports on ELAN. JPMorgan Chase & Co. raised Elanco Animal Health from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $18.00 to $24.00 in a report on Tuesday, October 7th. Morgan Stanley lifted their price target on Elanco Animal Health from $18.00 to $22.00 and gave the stock an “equal weight” rating in a research report on Thursday, December 18th. Wall Street Zen upgraded Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Stifel Nicolaus raised their target price on shares of Elanco Animal Health from $18.00 to $23.00 and gave the stock a “buy” rating in a research report on Wednesday, September 24th. Finally, Argus raised shares of Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a report on Wednesday, November 19th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $23.78.
Check Out Our Latest Stock Report on Elanco Animal Health
Elanco Animal Health Stock Up 2.4%
The company has a market capitalization of $11.72 billion, a price-to-earnings ratio of 393.15, a PEG ratio of 3.13 and a beta of 1.87. The company has a current ratio of 2.40, a quick ratio of 1.23 and a debt-to-equity ratio of 0.59. The firm’s 50 day simple moving average is $22.20 and its 200-day simple moving average is $19.08.
Elanco Animal Health (NYSE:ELAN – Get Free Report) last issued its earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share for the quarter, beating the consensus estimate of $0.13 by $0.06. The business had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.09 billion. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The business’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.13 earnings per share. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. On average, sell-side analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.
Insiders Place Their Bets
In related news, CFO Robert M. Vanhimbergen bought 6,950 shares of the stock in a transaction on Thursday, December 11th. The shares were bought at an average cost of $21.64 per share, for a total transaction of $150,398.00. Following the completion of the transaction, the chief financial officer owned 124,233 shares of the company’s stock, valued at $2,688,402.12. This represents a 5.93% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Rajeev A. Modi acquired 4,500 shares of Elanco Animal Health stock in a transaction that occurred on Thursday, December 11th. The shares were purchased at an average cost of $21.33 per share, with a total value of $95,985.00. Following the completion of the acquisition, the insider owned 123,082 shares of the company’s stock, valued at $2,625,339.06. The trade was a 3.79% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last three months, insiders have bought 43,450 shares of company stock worth $937,883. 0.89% of the stock is owned by insiders.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in the company. SJS Investment Consulting Inc. grew its stake in Elanco Animal Health by 2,563.5% in the 3rd quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock valued at $28,000 after acquiring an additional 1,333 shares during the last quarter. Huntington National Bank boosted its holdings in shares of Elanco Animal Health by 136.7% during the third quarter. Huntington National Bank now owns 1,882 shares of the company’s stock worth $38,000 after purchasing an additional 1,087 shares during the last quarter. Whittier Trust Co. of Nevada Inc. increased its stake in shares of Elanco Animal Health by 80.3% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock valued at $42,000 after acquiring an additional 900 shares during the last quarter. Farther Finance Advisors LLC raised its stake in Elanco Animal Health by 79.3% during the third quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock worth $43,000 after purchasing an additional 951 shares during the period. Finally, First Horizon Advisors Inc. boosted its holdings in Elanco Animal Health by 184.3% in the second quarter. First Horizon Advisors Inc. now owns 3,724 shares of the company’s stock valued at $53,000 after acquiring an additional 2,414 shares during the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.
About Elanco Animal Health
Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.
Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.